使用共识命名法估计脂肪性肝病及其亚分类的全国患病率
基于2017年1月至2020年3月美国国家健康与营养调查中7367名≥18岁且振动控制瞬时弹性成像数据完整的参与者,按多学会共识命名法定义脂肪性肝病(SLD)及其亚分类并估计全国患病率。估计SLD患病率为34.2%(95%CI 31.9%-36.5%),其中代谢功能障碍相关SLD(MASLD)31.3%、MASLD合并酒精摄入增加(MetALD)2%、酒精相关肝病(ALD)0.7%、病因特异性/隐源性0.03%;NAFLD与MASLD病例重叠99%。
要点
- 估计SLD全国患病率为34.2%(95%CI 31.9%-36.5%),其中MASLD占31.3%(95%CI 29.2%-33.4%)。
- MetALD估计患病率为2%(95%CI 1.6%-2.9%),ALD为0.7%(95%CI 0.5%-0.9%)。
- NAFLD与MASLD病例重叠99%,新命名法可用于弥补旧命名法的不足。
核心结论
- 研究结果突显新共识命名法在弥补旧命名法不足方面的实用性,并识别出需要进一步研究以完善SLD分类的领域。
研究设计与样本
- 使用2017年1月至2020年3月美国国家健康与营养调查数据,纳入所有≥18岁且振动控制瞬时弹性成像测量完整的参与者,共7367人。
- 按共识命名法定义SLD及其亚分类:MASLD、MASLD合并酒精摄入增加(MetALD)、酒精相关肝病(ALD)、病因特异性/隐源性。
- 估计全国SLD患病率及亚分类,并在年龄、性别、种族/民族、晚期肝纤维化(肝硬度值≥11.7 kPa)等关键亚组中分析。
主要发现
- 7367名参与者中2549例有SLD,平均年龄51岁,男性占57.7%,非西班牙裔白人占63.2%。
- 估计SLD患病率为34.2%(95%CI 31.9%-36.5%):MASLD 31.3%(95%CI 29.2%-33.4%),MetALD 2%(95%CI 1.6%-2.9%),ALD 0.7%(95%CI 0.5%-0.9%),病因特异性/隐源性0.03%(95%CI 0.01%-0.08%)。
- 探索性分析中,非SLD但伴晚期纤维化者(相比不伴晚期纤维化者)平均代谢危险因素数目更高[2.7(95%CI 2.3-3.1) vs 2.0(95%CI 1.9-2.0)],平均酒精使用≥20 g/d(女性)/≥30 g/d(男性)的比例更高[20.9%(95%CI 6.2%-51.3%) vs 7.2%(95%CI 6.1%-8.4%)]。
- 另一探索性分析中,低于MASLD合并酒精摄入增加阈值的酒精使用量增加与男性晚期肝纤维化相关,但与女性无关。
- NAFLD与MASLD病例重叠99%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The multisociety consensus nomenclature has renamed NAFLD to steatotic liver disease (SLD) with various subclassifications. There is a paucity of data regarding how the new nomenclature modifies our understanding of disease prevalence and patient phenotypes. APPROACH AND RESULTS: Using the National Health and Nutrition Examination Survey from January 2017 to March 2020, we included all participants aged 18 years or above with complete vibration-controlled transient elastography measures. SLD and its subclassifications [metabolic dysfunction-associated SLD (MASLD), MASLD + increased alcohol intake (MetALD), alcohol-associated liver disease (ALD), etiology-specific/cryptogenic] were defined according to consensus nomenclature. National SLD prevalence and subclassifications were estimated, and among key subgroups [age, sex, race/ethnicity, advanced liver fibrosis (liver stiffness measurement [LSM] ≥11.7 kPa)]. Among 7367 participants, 2549 had SLD (mean age 51 y, 57.7% male, 63.2% non-Hispanic White). The estimated prevalence of SLD was 34.2% (95% CI 31.9%-36.5%): MASLD 31.3% (29.2%-33.4%), MetALD 2% (1.6%-2.9%), ALD 0.7% (0.5-0.9%), etiology-specific/cryptogenic 0.03% (0.01%-0.08%). In exploratory analyses, participants classified as non-SLD with (vs. without) advanced fibrosis had a higher mean number of metabolic risk factors [2.7 (2.3-3.1) vs. 2.0 (1.9-2.0)] and a higher proportion with average alcohol use ≥20 g/d (women)/≥30 g/d (men) [20.9% (6.2%-51.3%) vs. 7.2% (6.1%-8.4%)]. In another exploratory analysis, increasing quantities of alcohol use remaining below the threshold for MASLD + increased alcohol intake were associated with advanced liver fibrosis in men, but not women. There was 99% overlap in cases of NAFLD and MASLD. CONCLUSIONS: Our findings highlight the utility of the new consensus nomenclature to address deficiencies present with the old nomenclature, and identify areas that require research to further refine classifications of SLD.
引用
- Lee BP, Dodge JL, Terrault NA, et al. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2023. PMID: 37732946. doi:10.1097/HEP.0000000000000604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。